BCDA · BioCardia, Inc.
$0.85
-0.06 (-6.26%)
At close · Jul 24
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed May 15, 2026
Market Cap
$9.67M
Shares
11.37M
BioCardia, Inc. Earnings Call Transcripts
Every quarterly earnings call for BioCardia, Inc. (BCDA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲1311.6%
$974,000
−$2.50M
'22 Q2
22-08-10
▼74.2%
$212,000
−$3.06M
'22 Q3
22-11-09
▲34.2%
$106,000
−$3.03M
'22 Q4
23-03-29
▲6.7%
$64,000
−$3.50M
'23 Q1
23-05-10
▼95.6%
$43,000
−$3.42M
'23 Q2
23-08-09
▲68.4%
$357,000
−$2.57M
'23 Q3
23-11-08
▼87.7%
$13,000
−$2.07M
'23 Q4
24-03-27
▼14.1%
$55,000
−$2.27M
'24 Q1
24-05-14
▼93%
$3,000
−$1.65M
'24 Q2
24-08-13
▼100%
$
−$1.74M
'24 Q3
24-11-13
▼100%
$
−$2.30M
'24 Q4
25-03-26
▼100%
$
−$2.71M
'25 Q1
25-05-14
▼100%
$
−$2.05M
'25 Q2
25-08-11
·
$
−$1.48M
'25 Q3
25-11-12
LATEST
·
$
−$1.98M
'25 Q4
26-03-24
Earnings call
FY26 · Q1
2026-05-15
BioCardia, Inc. Q1 FY2026 Earnings Call
Confident tone
Japan PMDA regulatory pathway
Market opportunity and reimbursement
Helix Transendocardial Delivery System
Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
BioCardia, Inc. Q4 FY2025 Earnings Call
Confident tone
Partnership and business development
CardiAMP HF Phase III results
Regulatory pathway and FDA/PMDA engagement
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
BioCardia, Inc. Q3 FY2025 Earnings Call
Positive tone
Japan PMDA regulatory progress
FDA regulatory engagement
Helix transendocardial delivery system
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
BioCardia, Inc. Q2 FY2025 Earnings Call
Positive tone
Japan PMDA Submission and Partnership Opportunity
CardiAMP Heart Failure Trial Results and Regulatory Pathway
Business Development and Partnering
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
BioCardia, Inc. Q1 FY2025 Earnings Call
Positive tone
Tariffs and Most Favored Nation Pricing
Business Development and Partnerships
Morph DNA Steerable Introducer Platform
Revenue
$
▼ 100% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-26
BioCardia, Inc. Q4 FY2024 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
BioCardia, Inc. Q3 FY2024 Earnings Call
Confident tone
Japan Regulatory Pathway (PMDA)
CardiAMP Heart Failure I Trial Readout
CardiAMP Heart Failure II Trial Enrollment
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
BioCardia, Inc. Q2 FY2024 Earnings Call
Positive tone
CardiALLO Allogeneic Cell Therapy
CardiAMP Heart Failure I Trial
Business Development and Partnerships
Revenue
$3,000
▼ 93% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
BioCardia, Inc. Q1 FY2024 Earnings Call
Confident tone
Japan PMDA Regulatory Pathway
CardiAMP Heart Failure Trial Results
Japanese Commercialization Strategy
Revenue
$55,000
▼ 14.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
BioCardia, Inc. Q4 FY2023 Earnings Call
Positive tone
Unmet Need in Heart Failure
Clinical Trial Execution and Enrollment
CardiAMP Heart Failure Trial (BCDA-01) Results
Revenue
$13,000*
▼ 87.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
BioCardia, Inc. Q3 FY2023 Earnings Call
Revenue
$357,000
▲ 68.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
BioCardia, Inc. Q2 FY2023 Earnings Call
Revenue
$43,000
▼ 95.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
BioCardia, Inc. Q1 FY2023 Earnings Call
Revenue
$64,000
▲ 6.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-29
BioCardia, Inc. Q4 FY2022 Earnings Call
Revenue
$106,000*
▲ 34.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
BioCardia, Inc. Q3 FY2022 Earnings Call
Revenue
$212,000
▼ 74.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
BioCardia, Inc. Q2 FY2022 Earnings Call
Revenue
$974,000
▲ 1311.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
BioCardia, Inc. Q1 FY2022 Earnings Call
Revenue
$60,000
▲ 30.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-29
BioCardia, Inc. Q4 FY2021 Earnings Call
Revenue
$79,000*
▲ 71.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q1
2021-05-13
BioCardia, Inc. Q1 FY2021 Earnings Call
Revenue
$46,000
▲ 21.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
BioCardia, Inc. Q4 FY2020 Earnings Call
Revenue
$46,000*
▼ 78.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q2
2020-08-13
BioCardia, Inc. Q2 FY2020 Earnings Call
Revenue
$27,000
▼ 68.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–21 of 21 earnings calls